Serological studies of adenoviral hepatitis following pediatric liver transplantation by Koneru, B et al.
Serological Studies of Adenoviral Hepatitis Following Pediatric 
Liver Transplantation 
B. Koneru, R. Atchison, R. Jaffe, A. Cassavilla, D.H. Van Thiel, and T.E. Starzl 
I NFECTIONS with the herpes group of viruses are the 
most common viral infections following pediatric liver 
transplantation. I Adenoviral infections, though uncom-
mon, are being increasingly recognized following organ 
transplantationKOK~ We have previously reported our initial 
experience with adenoviral infections in children receiving 
liver transplants. 6 Subsequently. our experience has fur-
ther increased and is being reported to amplify our initial 
observations. Also, serological studies of donor and recip-
ient sera were performed to help understand the type and 
mode of infection. An attempt was made to correlate these 
data to patients' clinical course. 
MATERIALS AND METHODS 
During a 7-month period. 10 of 393 (2.5%) pediatric liver recipi-
ents developed adenoviral hepatitis. Diagnosis was made by 
percutaneous liver biopsy in 9 patients (90%). Histological fea-
tures were characteristic with circumscribed foci of necrosis in the 
hepatic lobule with infiltration of monocytes. Diagnosis was 
confirmed by immunohistochemical staining. 
Donor sera were obtained from blood samples drawn at the time 
of organ procurement. Recipient sera were obtained from blood 
samples drawn just prior to the transplant. Sera were stored 
frozen at - 20"C. Portions of each serum available for viral 
antibody study were coded. refrozen (-70"C). and later thawed 
for anonymous. simultaneous testing. 
Neutralization Tests: Adenovirus type specific neutralizing 
antibody titers were determined against known adenovirus types 
I through 5 for all samples in the study. Briefly. serial 2-fold 
dilutions of each sample "'ere made in duplicate in 96-well plastic 
tissue culture plates (:-';unclon. Gibeo) in 0.025 mL volumes. using 
complete cell culture maintenance medium. Each well received 
0.025 mL of the respective adenovirus type, diluted to contain 
from 300 to 1000 TCID50 units of virus in 0.025 mL. Plates were 
placed in a humidified chamber of a standard cell culture incubator 
for up to 7 days. Results were read at the time of appearance of 
specific cytopathic effect (CPE). Assignment of neutralizing titer 
was made using the highest of the paired serum dilutions (wells) 
showing absence of CPE. 
Adenol'iruses: Each of the adenovirus types were purchased 
from the American Type Culture CoUection (Bethesda. MD), and 
verified as to serotype against 2 to 8 neutralizing units of a known 
type-specific serum (CDC source: Dr W. McD. Hammon). The 
adenovirus strains used 'Were: type-I VR-I, type-2 Adenoid 6. 
type-3 GB. type-4 RI-67. and type-S Adenoid 75. 
Cells and Media: HEP-2 (human laryngeal epidermoid carci-
noma cell line) were grown in plastic lIasks to conlluent mono-
layers. Cell growth medium was Eagle's Minimum Essential 
Medium supplemented with 8% inactivated newborn calf serum, 
25 rnmollL Hepes. 100 units of penicillin G and 100 1-'8 of 
streptomycin sulfate per mL. Cells were verified to be free of 
mycoplasma contamination. by Hoechst 33258 staining at the time 
of use. 
RESULTS 
Neutralizing antibody titers of 1:4 or greater were consid-
ered positive. Antibody titers to only the relevant serotype 
in a given patient are shown in Table I. 
or the 10 patients with the A V hepatitis, 3 recovered 
spontaneously with lowering of immunosuppression (pa-
tients 2, 3, and 10). Two of these 3 patients had high titers 
of type specific neutralizing antibodies at transplantation. 
Four progressed to massive liver necrosis (patients 4, 5, 6, 
and 9) and only I among them had neutralizing antibodies 
at a low titer of IA. Retransplantation was attempted in 3 
of the patients with massive liver necrosis, 2 succumbing 
. during surgery. Interestingly. the lone survivor did not 
develop recurrent A V hepatitis. The remaining 3 (patients 
I, 7, and 8) had coexisting problems (Iymphoproliferative 
disorder, chronic rejection. and abdominal sepsis). Only I 
of these 3 patients survived following retransplantation for 
combined rejection and A V hepatitis. This patient also did 
not develop recurrence of hc:patitis. 
DISCUSSION 
Adenoviral infections are being increasingly recognized in 
organ transplant recipients. =K~ In our previous report we 
described the features of 5 cases of A V hepatitis among a 
total of 22 children with A V infections after liver 
transplantation.6 Further experience since then has cor-
roborated our initial clinico-pathological observations. 
Even though A V hepatitis occurred in only 2.5% of all 
pediatric liver recipients it '" as the second most common 
viral infection of the hepatic allograft next only to cyto-
megalovirus infections. 
Histological features are characteristic and immunohis-
tochemistry confirms the diagnosis very quickly. With 
increasing experience we have relied less on electron 
microscopic demonstration of the virus. Culture of the 
virus is not necessary for the diagnosis, but it should be 
pursued for serotyping and other studies. Although several 
serotypes have been shown to cause hepatitis, serotype 5 
From the Depattments of Surgery, Pathology, and Medicine and 
the Graduate School of Public Health, University of Pittsburgh, 
Pittsburgh, Pennsylvania. 
Address reprint requests to Baburao Koneru, E-325, University 
Hospital, 150 Bergen Street, Newaric, NJ 07103. 
@ 1990 by Appleton & Lange 
0041·134s.c301$3.001 + 0 
Transplantation Proceedings, Vol 22, No 4 (August), 1990: pp 1547-1548 
- - - --- --~-~ --- -
1548 KONERU, ATCHISON, JAFFE ET AL 
Table 1. Results of Antibody TIters and Clinical Course of 10 Children With AV Hepatitis 
Patient 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
NA = serum not available. 
Serotype 
5 
5 
5 
5 
5 
5 
2 
5 
Donor 
NA 
NA 
Neg 
1:<2 
NA 
Pos 
1 :4 
Pos 
1 :4 
Pos 
1 :4 
NA 
Pos 
1 :32 
Pos 
1:4 
has been the most common pathogen in the bone marrow 
recipients and also in our experience. 
All cases of A V hepatitis with available serological data 
in our series show that either the donor or the recipient 
were seropositive at the time of the transplant. This 
supports our belief that the infection is either transmitted 
through the donor organ or is a reactivation of a latent 
recipient infection. The majority of our recipients (67%} 
were seronegative at the time of the transplant and were at 
risk for "primary" infection. This is in contrast to the 
experience of Shields et ae with bone marrow recipients. 
among whom a high percentage were found to have 
preexisting neutralizing antibodies suggesting that these 
infections may be due to "reactivation" of a latent recip-
ient infection. The lower incidence of seropositivity in our 
recipients is probably related to the majority of recipients 
being less than 5 years of age. Our experience also 
suggests that A V hepatitis may have greater propensity 
toward massive liver necrosis in recipients that do not 
have preexisting antibodies. 
The case fatality rate for A V hepatitis in our series was 
high at 30%. The absence of any known effective chemo-
therapeutic agent makes treatment of A V hepatitis. other 
than lowering of immunosuppressive therapy difficult. 
Recipient Result 
NA Retransplanted; recovered 
Pos RecoYefed 
1:64 
Pos Recovered 
1 :6 
Pos Died 
1 :4 
Neg Died during retransplanl 
1:<2 
Neg Retransplanted; recovered 
1:2 
Neg Died during retransplam 
1 :<2 
Neg Died 
1 :<2 
Neg Died during retransplanl 
1:<2 
Neg Recovered 
1:<2 
There have been sporadic reports of the use of immuno-
globulin and thymic humoral factor with fa\'orable 
results. 8 .9 Massive liver necrosis and fulminant liver fail-
ure require retransplantation. The absence of recurrence 
of A V hepatitis in the second allograft in the 2 survivors of 
retransplantation suggests that this may be a prudent 
policy. 
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